Similarly, in a melanoma mouse model, CTLA-4 blockade cooperated with radiotherapy to increase the CD8 effector T cell to Treg ratio and diversify the T cell receptor (TCR) repertoire resulting in therapeutic synergy. This evidence concerns the gene CTLA4 and melanoma.